137 related articles for article (PubMed ID: 22102461)
41. A claims-based view of health care charges and utilization for commercially insured patients with osteoarthritis.
Dunn JD; Pill MW
Manag Care; 2009 Dec; 18(12):44-50. PubMed ID: 20088148
[TBL] [Abstract][Full Text] [Related]
42. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
[TBL] [Abstract][Full Text] [Related]
43. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
44. Predicting pharmacy costs and other medical costs using diagnoses and drug claims.
Zhao Y; Ash AS; Ellis RP; Ayanian JZ; Pope GC; Bowen B; Weyuker L
Med Care; 2005 Jan; 43(1):34-43. PubMed ID: 15626932
[TBL] [Abstract][Full Text] [Related]
45. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
46. Direct medical costs for patients seeking emergency care for losses of epilepsy control in a U.S. managed care setting.
Zachry WM; Doan QD; Smith BJ; Clewell JD; Griffith JM
Epilepsy Behav; 2009 Oct; 16(2):268-73. PubMed ID: 19747882
[TBL] [Abstract][Full Text] [Related]
47. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
48. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
[TBL] [Abstract][Full Text] [Related]
49. Pain conditions ranked by healthcare costs for members of a national health plan.
Pasquale MK; Dufour R; Schaaf D; Reiners AT; Mardekian J; Joshi AV; Patel NC
Pain Pract; 2014 Feb; 14(2):117-31. PubMed ID: 23601620
[TBL] [Abstract][Full Text] [Related]
50. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.
Park KT; Colletti RB; Rubin DT; Sharma BK; Thompson A; Krueger A
Am J Gastroenterol; 2016 Jan; 111(1):15-23. PubMed ID: 26195179
[TBL] [Abstract][Full Text] [Related]
51. Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma.
Kruse GB; Potashman MH; Stavrakas S; Wong BJ
J Med Econ; 2014 Jul; 17(7):446-58. PubMed ID: 24758228
[TBL] [Abstract][Full Text] [Related]
52. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.
Harris L; Graham S; MacLachlan S; Exuzides A; Jacob S
J Med Econ; 2019 Jul; 22(7):691-697. PubMed ID: 30841772
[No Abstract] [Full Text] [Related]
53. The economic burden of diagnosed opioid abuse among commercially insured individuals.
Rice JB; Kirson NY; Shei A; Enloe CJ; Cummings AK; Birnbaum HG; Holly P; Ben-Joseph R
Postgrad Med; 2014 Jul; 126(4):53-8. PubMed ID: 25141243
[TBL] [Abstract][Full Text] [Related]
54. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
Furlan JC; Barth D; Barnett C; Bril V
Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
[TBL] [Abstract][Full Text] [Related]
55. Direct and indirect cost of myasthenia gravis: A prospective study from a tertiary care teaching hospital in India.
Sonkar KK; Bhoi SK; Dubey D; Kalita J; Misra UK
J Clin Neurosci; 2017 Apr; 38():114-117. PubMed ID: 27887977
[TBL] [Abstract][Full Text] [Related]
56. [Discretionary decisions in claims data analyses and their effects - an explorative comparison using the example of a cost of illness study on dementia].
Schwarzkopf L; Menn P; Holle R
Gesundheitswesen; 2012 Aug; 74(8-9):e76-83. PubMed ID: 22932829
[TBL] [Abstract][Full Text] [Related]
57. Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.
Fang W; Li Y; Mo R; Wang J; Qiu L; Ou C; Lin Z; Huang Z; Feng H; He X; Wang W; Xu P; Wang L; Ran H; Liu W
Neurol Sci; 2020 May; 41(5):1211-1223. PubMed ID: 31897952
[TBL] [Abstract][Full Text] [Related]
58. Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States.
Parthan A; Royston M; Thanataveerat A; East EL; Parzynski CS; Habib AA
Muscle Nerve; 2024 Feb; 69(2):157-165. PubMed ID: 38018505
[TBL] [Abstract][Full Text] [Related]
59. Out-of-pocket expenses for myasthenia gravis patients in China: a study on patients insured by basic medical insurance in China, 2013-2015.
Lin TY; Zhang XY; Fang PQ; Min R
Orphanet J Rare Dis; 2020 Jan; 15(1):13. PubMed ID: 31937334
[TBL] [Abstract][Full Text] [Related]
60. Cost of illness for neuromuscular diseases in the United States.
Larkindale J; Yang W; Hogan PF; Simon CJ; Zhang Y; Jain A; Habeeb-Louks EM; Kennedy A; Cwik VA
Muscle Nerve; 2014 Mar; 49(3):431-8. PubMed ID: 23836444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
